Meiji pays for Thai and Indonesian rights to pruritus drug

21 January 2019

Japanese companies Meiji Seika Pharma and Toray Industries (TYO: 3402) have signed a licensing agreement for the development and commercialization of the antipruritic drug, TRK-820 (nalfurafine hydrochloride), in Thailand and Indonesia.

Meiji will pay an undisclosed upfront fee and milestone payments on any sales of TRK-820, which is marketed as Remitch in Japan and is prescribed to improve pruritus in hemodialysis patients and in chronic liver disease.

Thailand has a large number of end-stage renal disease patients and it is one of the countries with high needs for hemodialysis treatments. Until now, both Thai patients and Indonesians have not had access to effective drugs to ease pruritus of dialysis and chronic liver disease.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK